Former Emisphere investors sue following sale to Novo Nordisk

The USD 1.8bn price does not reflect the value of Emisphere, according to former Emisphere shareholders, who have sued MHR Fund Management.

Photo: Novo Nordisk / PR

Last year, Novo Nordisk bought US company Emisphere Technologies for USD 1.8bn. Former investors in Emisphere are now suing the company's largest shareholder, MHR Fund Management, according to Fierce Pharma.

Iszo, a New York-based investment fund, accuses MHR of manipulating the Emisphere board to sell the company at an inconvenient time at an artifically low price.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs